Hypomorphic <i>ATP11c</i> is a novel regulator of decreased efficacy of transfused red blood cells in humans and mice.

Pubmed ID: 41523080

Pubmed Central ID: PMC12784117

Journal: HemaSphere

Publication Date: Jan. 9, 2026

Grants: R01 HL146442, R01 HL149714

Authors: Busch MP, Kleinman S, Norris PJ, Page GP, Stephenson D, Keele GR, Dzieciatkowska M, Zimring JC, D'Alessandro A, Haiman ZB, Roubinian N, Hay AM, Fermo E, Bianchi P

Cite As: Zimring JC, Hay AM, Dzieciatkowska M, Stephenson D, Haiman ZB, Kleinman S, Norris PJ, Busch MP, Roubinian N, Fermo E, Bianchi P, Keele GR, Page GP, D'Alessandro A. Hypomorphic ATP11c is a novel regulator of decreased efficacy of transfused red blood cells in humans and mice. Hemasphere 2026 Jan 9;10(1):e70288. doi: 10.1002/hem3.70288. eCollection 2026 Jan.

Studies:

Abstract

Chronic red blood cell (RBC) transfusion sustains patients with diverse hematologic disorders, but repeated transfusion leads to iron overload and alloimmunization. Reducing transfusion burden requires identifying donor units that circulate more effectively after storage, yet determinants of this variability remain incompletely defined. Here, we integrate forward genetics in mice, multi-omics analyses of over 13,000 human donors, and studies of two families with hereditary ATP11c mutations to reveal a central role for this phospholipid flippase in transfusion efficacy. We show that common ATP11C variants, including the missense SNP V972M, and rare familial loss-of-function alleles impair RBC survival by disrupting membrane lipid remodeling and cytoskeletal stability-a mechanism distinct from oxidative damage pathways. Together, these findings establish ATP11c as a novel determinant of transfusion outcomes across species and genetic contexts, and highlight opportunities for donor stratification and improved storage technologies to advance precision transfusion medicine.